RESUMEN
OBJECTIVE: To examine the association between maternal alcohol consumption during pregnancy and the risk of preterm delivery. DESIGN: Prospective cohort study. SETTING: The Japan Environment and Children's Study (JECS). POPULATION: A total of 94 349 singleton pregnancies. METHODS: Participants completed questionnaires detailing alcohol consumption during the first trimester and during the second and third trimesters. Participants were divided into four categories according to alcohol consumption (non-drinkers, consumers of 1-149 g, 150-299 g and ≥300 g ethanol/week). We examined the effect of alcohol consumption during different stages of pregnancy on the risk of preterm delivery. Odds ratios (OR) and 95% CI were calculated relative to non-drinkers using logistic regression. MAIN OUTCOME MEASURES: Medical record-based preterm delivery. RESULTS: Alcohol consumption during the second and third trimesters, but not during the first trimester, was associated with increased risk of preterm delivery. Heavy alcohol consumption (≥300 g ethanol/week) during the second and third trimesters was associated with a four-fold higher risk compared with non-drinkers (multivariable OR 4.52; 95% CI 1.68-12.2). Light alcohol consumption (1-149 g ethanol/week) tended to be associated with lower risk of preterm delivery (multivariable OR 0.78; 95% CI 0.60-1.00). CONCLUSIONS: Heavy alcohol consumption during the second and third trimesters was associated with increased risk of preterm delivery among pregnant women. TWEETABLE ABSTRACT: Heavy drinking during pregnancy may increase the risk of preterm delivery.
Asunto(s)
Consumo de Bebidas Alcohólicas/efectos adversos , Nacimiento Prematuro/epidemiología , Adulto , Estudios de Cohortes , Femenino , Humanos , Japón/epidemiología , Servicios de Salud Materno-Infantil , Embarazo , Segundo Trimestre del Embarazo , Tercer Trimestre del Embarazo , Nacimiento Prematuro/etiología , Estudios Prospectivos , Factores de Riesgo , Encuestas y CuestionariosRESUMEN
Using the nationwide health insurance claims database, we found that the age-standardized hip fracture incidence rates in Japan indicated significant increase in males but no significant change in females during 2012-2015. The fracture risk in subjects aged 75-84 years indicated decrease in females but no change in males. INTRODUCTION: Nationwide registry data on hip fractures have not yet been established in Japan. Using the newly developed National Database of Health Insurance Claims (NDB), which covers the entire Japanese population, we investigated the incidence rates of hip fractures and the associated regional differences. We also assessed the frequency of osteoporosis prescriptions, bone turnover marker (BTM) level, and bone mineral density (BMD) measurements. METHODS: The annual numbers of hip fractures, osteoporosis prescriptions, and BTM level and BMD measurements by prefecture from 2012 to 2015 were obtained from NDB data. We calculated the standardized claims-data ratio (SCR) in each prefecture. RESULTS: The age-standardized incidence rates from 2012 to 2015 indicated no significant change in females and significant increase in males (p value for trend; 0.920, 0.002, respectively). The fracture risk decreased in females aged 75-84 years and indicated no increase in females aged 85-89 years during 2012-2015, while the fracture risk indicated no change in males aged 75-84 years and increased in males aged 85-89 years. The frequency of osteoporosis prescriptions, BTM level measurements, and BMD measurements in the general population in the corresponding period increased with statistical or marginal significance in females and males. West-east regional differences were observed in the incidence rates; the highest SCR values in the western prefectures were approximately double the lowest values in the eastern prefectures. CONCLUSIONS: The age-standardized hip fracture incidence rates indicated no significant change in females and significant increase in males in Japan from 2012 to 2015.
Asunto(s)
Fracturas de Cadera/epidemiología , Fracturas Osteoporóticas/epidemiología , Distribución por Edad , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Densidad Ósea/fisiología , Conservadores de la Densidad Ósea/uso terapéutico , Remodelación Ósea/fisiología , Bases de Datos Factuales , Prescripciones de Medicamentos/estadística & datos numéricos , Femenino , Fracturas de Cadera/fisiopatología , Fracturas de Cadera/prevención & control , Humanos , Incidencia , Japón/epidemiología , Masculino , Osteoporosis/tratamiento farmacológico , Osteoporosis/epidemiología , Fracturas Osteoporóticas/fisiopatología , Fracturas Osteoporóticas/prevención & control , Distribución por SexoRESUMEN
Dehydroxymethylepoxyquinomicin (DHMEQ), a new nuclear factor (NF)-κB inhibitor, has several beneficial effects, including the suppression of tumour growth and anti-inflammatory effects. DHMEQ can also suppress the production of tumour necrosis factor (TNF)-α induced by lipopolysaccharide (LPS) in vitro. In the present study, we examine the effects of DHMEQ on TNF-α production in vivo and on the survival of mice injected with LPS. When DHMEQ was injected into mice 2 h before LPS injection, the survival of the LPS-injected mice was prolonged. When DHMEQ was injected twice (2 h before LPS injection and the day after LPS injection), all the mice were rescued. The injection of DHMEQ 1 h after LPS injection and the day after LPS injection also resulted in the rescue of all mice. The serum levels of TNF-α in the mice that received both LPS and DHMEQ were suppressed compared to the mice that received only LPS. These results suggest that DHMEQ can be utilized for the prevention and treatment of endotoxin shock.
Asunto(s)
Benzamidas/farmacología , Ciclohexanonas/farmacología , Choque Séptico/tratamiento farmacológico , Choque Séptico/inmunología , Factor de Necrosis Tumoral alfa/biosíntesis , Animales , Apoptosis/efectos de los fármacos , Núcleo Celular/metabolismo , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Interleucina-1beta/biosíntesis , Interleucina-6/biosíntesis , Lipopolisacáridos/inmunología , Masculino , Ratones , Ratones Endogámicos C57BL , FN-kappa B/metabolismo , ARN Mensajero/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Choque Séptico/prevención & control , Bazo/citología , Factor de Necrosis Tumoral alfa/sangreRESUMEN
The exact origin of neural stem cells in the adult neurogenesis niche remains unknown. Our previous studies, however, indicated an implication of both bone marrow cells as potential progenitors of hippocampal newborn neurons and polyunsaturated fatty acids as ligands of G protein-coupled receptor 40 (GPR40) signaling. Here, we aimed at studying whether bone marrow-derived stromal cells (BMSC) treated by docosahexaenoic acid (DHA) can express neuronal markers in vitro. We focused on implication of DHA/GPR40 signaling for the expression of neural markers in clonally-expanded BMSC from young macaque monkeys. Cell cycle analysis revealed that the DHA plus bFGF treatment induced a decrease of BMSC proliferation and increased the cells in the G0 resting phase. The transitions from nestin-positive progenitors via immature neuronal (beta III-tubulin-positive) to mature neuronal (NF-M and Map2-positive) phenotypes were examined using RT-PCR, Western blot and immunocytochemistry. We detected a significant increase of GPR40 mRNA and protein expression after bFGF induction, being compared with the untreated BMSC. Addition of DHA, a representative GPR40 ligand, led to a significant down-regulation of GPR40, i.e., G protein-coupled receptor-specific internalization, with a subsequent upregulation of neuronal markers such as beta III-tubulin, NF-M and Map2. These data altogether suggest that adult primate BMSC can express neuronal markers with the aid of DHA/GPR40 signaling.
Asunto(s)
Biomarcadores/metabolismo , Células de la Médula Ósea , Ácidos Docosahexaenoicos/farmacología , Neuronas/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Transducción de Señal/fisiología , Células del Estroma , Animales , Células de la Médula Ósea/citología , Células de la Médula Ósea/efectos de los fármacos , Células de la Médula Ósea/metabolismo , Ciclo Celular/fisiología , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Células Cultivadas , Macaca , Neuronas/citología , Fenotipo , Células del Estroma/citología , Células del Estroma/efectos de los fármacos , Células del Estroma/metabolismoRESUMEN
We have developed a new BMT method, intra-BM-BMT (IBM-BMT), in which donor BM cells (BMCs) are directly injected into the recipient's BM, resulting in a rapid recovery of donor hematopoiesis and a reduction in the severity of GVHD. In the present experiment, we attempted to retain the number of injected BMCs using magnetic beads and a magnet. The BMCs of donor mice were conjugated with magnetic beads, and these cells were then injected into the BM of recipient mice with a magnet (magnet-IBM group) and compared with conventional IBM-BMT without a magnet (IBM group). A significantly higher number of transplanted cells were detected in the injected BM in the magnet-IBM group. We next carried out day-12 colony-forming units of spleen (CFU-S) assays to examine the early stage of hematopoiesis of the injected host hematopoietic stem cells after IBM-BMT. The spleens of mice in the magnet-IBM group showed considerably higher CFU-S counts than those in the IBM group. Excellent reconstitution of donor hematopoietic cells in the magnet-IBM group was observed 1 month after IBM-BMT. These results suggest that the IBM-BMT using the combination of magnetic beads and a magnet is superior to the conventional IBM-BMT.
Asunto(s)
Trasplante de Médula Ósea/métodos , Médula Ósea/fisiología , Hematopoyesis , Separación Inmunomagnética/métodos , Donantes de Tejidos , Animales , Recuento de Células , Ensayo de Unidades Formadoras de Colonias , Enfermedad Injerto contra Huésped , Inyecciones , Ratones , Regeneración , Bazo/citología , Bazo/fisiologíaRESUMEN
We examined the effects of intra-BM-BMT (IBM-BMT) plus adult thymus transplantation (ATT) from the same donor after 5.5 Gy sublethal irradiation (SubLI) or low-dose (3 x 10(6)) BM cell injection (LDBMCI). With SubLI, BALB/c mice that had received 1 x 10(7) bone marrow cells by IBM-BMT plus ATT from B6 mice showed 73% donor chimerism, whereas those treated with IBM-BMT alone showed 45% chimerism. In the LDBMCI with 7Gy irradiation, IBM-BMT plus ATT resulted in a 90% survival rate with 90% chimerism, whereas IBM-BMT alone resulted in a 55% survival rate with 44% chimerism. Although the number of CD4 T cells was higher in IBM-BMT plus ATT than in IBM-BMT alone, the percentages of FoxP3+/CD4+ T cells and lymphocyte functions in the former were almost identical to those in the latter. When treated with IBM-BMT plus donor lymphocyte infusion (DLI), the mice showed a reduced survival time as a result of GVHD, with low numbers of FoxP3+CD4 T cells under either condition, although 100% chimerism was induced. These results suggest that IBM-BMT plus ATT is effective in reconstituting the recipients with donor-derived cells even after SubLI or LDBMCI.
Asunto(s)
Trasplante de Médula Ósea , Supervivencia de Injerto , Timo/trasplante , Animales , Peso Corporal , Trasplante de Médula Ósea/inmunología , Trasplante de Médula Ósea/métodos , Femenino , Intestino Delgado/patología , Hígado/patología , Linfocitos/inmunología , Ratones , Ratones Endogámicos BALB C , Bazo/inmunología , Tasa de Supervivencia , Timo/inmunología , Timo/patología , Quimera por Trasplante/inmunología , Tolerancia al Trasplante/inmunología , Trasplante Homólogo , Resultado del Tratamiento , Irradiación Corporal TotalRESUMEN
(NZW x BXSB)F1 mice (W/BF1 mice) have been reported to be a type of autoimmune-prone mice, showing symptoms of proteinuria, anti-DNA antibodies and anti-platelet antibodies. In this paper, we report that W/BF1 mice show hyperproduction of tumour necrosis factor (TNF)-alpha, responding to lipopolysaccharide (LPS) in comparison with normal mice, resulting in induction of death. In normal mice, monocytes/macrophages (Mo/MØ) are the main producer of TNF-alpha, while both Mo/MØ and dendritic cells (DCs) produce TNF-alpha in W/BF1 mice. Because the number of DCs is higher in W/BF1 mice, the main producers of TNF-alpha in W/BF1 mice are thought to be DCs. Moreover, administration of anti-TNF-alpha antibodies rescued the W/BF1 mice from death induced by LPS, suggesting that TNF-alpha is crucial for the effect of LPS. Although there is no significant difference in the expression of Toll-like receptor-4 (TLR-4) on DCs between B6 and W/BF1 mice, nuclear factor kappa b activity of DCs from W/BF1 mice is augmented under stimulation of LPS in comparison with that of normal mice. These results suggest that the signal transduction from TLR-4 is augmented in W/BF1 mice in comparison with normal mice, resulting in the hyperproduction of TNF-alpha and reduced survival rate. The results also suggest that not only the quantity of endotoxin, but also the host conditions, the facility to translate signal from TLR, and so on, could reflect the degree of bacterial infections and prognosis.
Asunto(s)
Enfermedades Autoinmunes/inmunología , Células Dendríticas/inmunología , Lipopolisacáridos/toxicidad , Factor de Necrosis Tumoral alfa/biosíntesis , Animales , Relación Dosis-Respuesta Inmunológica , Femenino , Lipopolisacáridos/inmunología , Masculino , Ratones , Ratones Endogámicos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Transducción de Señal/inmunología , Bazo/inmunología , Análisis de Supervivencia , Receptor Toll-Like 4/metabolismo , Factor de Necrosis Tumoral alfa/inmunologíaRESUMEN
We have developed a new and effective method for bone marrow transplantation (BMT): bone marrow cells (BMCs) are injected directly into the bone marrow (BM) cavity of recipient mice. The intrabone marrow injection of BMCs (IBM-BMT) greatly facilitates the engraftment of donor-derived cells, and IBM-BMT can attenuate graft-versus-host reaction (GVHR), in contrast to conventional intravenous BMT (i.v.-BMT). Here, we examine the mechanisms underlying the inhibitory effects of IBM-BMT on GVHR using animal models where GVHR is elicited. Recipient mice (C57BL/6) were irradiated and splenic T cells (as donor lymphocyte infusion: DLI) from major histocompatibility complex-disparate donors (BALB/c) were injected directly into the BM cavity (IBM-DLI) or injected intravenously (i.v.-DLI) along with IBM-BMT. The BM stromal cells (BMSCs) from these recipients were collected and related cytokines were examined. The recipient mice that had been treated with IBM-BMT + i.v.-DLI showed severe graft-versus-host disease (GVHD), in contrast to those treated with IBM-BMT + IBM-DLI. The suppressive activity of BMSCs in this GVHD model was determined. The cultured BMSCs from the recipients treated with IBM-BMT + IBM-DLI suppressed the proliferation of responder T cells remarkably when compared with those from the recipients of IBM-BMT + i.v.-DLI in mixed leucocyte reaction. Furthermore, the level of transforming growth factor-beta and hepatocyte growth factor in cultured BMSCs from IBM-BMT + IBM-DLI increased significantly when compared with those from the recipients of IBM-BMT + i.v.-DLI. Thus, the prevention of GVHD observed in the recipients of IBM-BMT + IBM-DLI was attributable to the increased production of immunosuppressive cytokines from BMSCs after interaction with host reactive T cells (in DLI).
Asunto(s)
Trasplante de Médula Ósea/métodos , Enfermedad Injerto contra Huésped/prevención & control , Transfusión de Linfocitos/métodos , Células del Estroma/inmunología , Animales , Células de la Médula Ósea/inmunología , Proliferación Celular , Células Cultivadas , Técnicas de Cocultivo , Enfermedad Injerto contra Huésped/inmunología , Factor de Crecimiento de Hepatocito/biosíntesis , Tolerancia Inmunológica , Interferón gamma/biosíntesis , Interleucina-3/biosíntesis , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/trasplante , Factor de Crecimiento Transformador beta/biosíntesisRESUMEN
OBJECTIVES: Femoral head osteonecrosis (ON) is a serious complication of steroid administration. We evaluated bone marrow transplantation (BMT) for preventing corticosteroid-induced ON. METHODS: Rabbits, injected with methylprednisolone (MPSL; 20 mg/kg), were divided into four groups: (i) MPSL alone; MPSL injection only, (ii) MPSL+needling; 2 days after MPSL injection, a hole (1.2 mm diameter) was drilled from the outer cortex 2.5 cm distal to the proximal end of the greater trochanter, (iii) MPSL+saline; 2 days after MPSL injection, 2 ml saline was injected directly into the bone marrow cavity, and (iv) MPSL+BMT; 2 days after MPSL injection, 1 x 10(7)/2 ml bone marrow cells (BMCs) were injected directly into the bone marrow cavity. Platelets, fibrinogen, prothrombin time and total cholesterol in peripheral blood were measured before and after treatment. Tissues were stained with haematoxylin and eosion and terminal deoxynucleotidyl-mediated deoxyuridine triphosphate nick-end labelling stain and immunostained for VEGF, while cell proliferation and viability of whole BMCs in the femur were analysed by cell cycle analysis and [(3)H]-thymidine uptake. RESULTS: The ON incidence in rabbits treated with MPSL alone, MPSL+needling and MPSL+saline was 72.7, 70.0 and 66.7%, respectively, while in the MPSL+BMT group, the incidence was 0%. Serological findings in the MPSL+BMT group were almost normalized. VEGF and TUNEL staining were reduced in the MPSL+BMT group compared with all other groups. There were significantly fewer BMCs in G1 phase from the MPSL+BMT group than the other groups, while uptake of [(3)H]-thymidine was significantly increased. CONCLUSION: Direct injection of autologous BMCs into femurs prevents corticosteroid-induced ON following treatment with high-dose, short-term steroids.
Asunto(s)
Trasplante de Médula Ósea/métodos , Necrosis de la Cabeza Femoral/inducido químicamente , Necrosis de la Cabeza Femoral/prevención & control , Glucocorticoides/efectos adversos , Metilprednisolona/efectos adversos , Animales , Apoptosis , Coagulación Sanguínea , Ciclo Celular/efectos de los fármacos , Esquema de Medicación , Femenino , Cabeza Femoral/patología , Necrosis de la Cabeza Femoral/patología , Fibrinólisis , Etiquetado Corte-Fin in Situ , Inyecciones , Modelos Animales , Osteoblastos/trasplante , Osteoclastos/trasplante , Conejos , Trasplante Autólogo , Factor A de Crecimiento Endotelial Vascular/análisisRESUMEN
The male Wistar Bonn/Kobori (WBN/Kob) rat is known to be a unique animal model for chronic pancreatitis with widely distributed fibrosis and degeneration of parenchyma because of the infiltration of lymphocytes. In this report, we show that female (but not male) rats develop dacryoadenitis at 3 months of age, and that both male and female WBN/Kob rats develop sialoadenitis, thyroiditis, sclerotic cholangitis and tubulointerstitial nephritis over 18 months of age. The infiltration of CD8+ cells and the deposits of tissue-specific IgG2b were observed in the injured pancreas and lachrymal glands. Furthermore, the number of regulatory T cells (defined as CD4+ Forkhead box P3+ cells) decreased in the periphery of both male and female WBN/Kob rats, suggesting that the onset of these diseases is attributable, at least, to the failure in the maintenance of peripheral immune tolerance. These features show clearly that WBN/Kob rats are a useful animal model for autoimmune pancreatitis and Sjøgren-like syndrome or multi-focal fibrosclerosis in humans. We also show that these autoimmune diseases can be prevented by a newly devised strategy of bone marrow transplantation (BMT) in which bone marrow cells are injected directly into the bone marrow cavity: intrabone marrow-BMT.
Asunto(s)
Enfermedades Autoinmunes/patología , Dacriocistitis/patología , Modelos Animales de Enfermedad , Pancreatitis Crónica/patología , Animales , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/prevención & control , Trasplante de Médula Ósea/métodos , Linfocitos T CD4-Positivos/patología , Linfocitos T CD8-positivos/patología , Dacriocistitis/inmunología , Dacriocistitis/prevención & control , Femenino , Técnicas para Inmunoenzimas , Inmunoglobulina G/biosíntesis , Riñón/patología , Hígado/patología , Masculino , Pancreatitis Crónica/inmunología , Pancreatitis Crónica/prevención & control , Ratas , Ratas Endogámicas F344 , Ratas Wistar , Glándula Tiroides/patologíaRESUMEN
We attempted to rescue supralethally irradiated (SLI) mice by transplantation of hematopoietic stem cells (HSCs) plus thymus from variously aged donors (fetus, newborn and adult). Although the transplantations of these kinds of HSCs alone showed a very short survival, newborn liver cells (NLCs) (as the source of HSCs) plus newborn thymus (NT) transplantation markedly improved the survival rate. The transplantation attenuated severe damage in the small intestine, which is one of the major causes of death by SLI. In addition, the donor-derived CD4(+) T cells significantly increased with additional NT transplantation. The production of interleukin (IL)-7 and keratinocyte growth factor, which plays a crucial role in protection against radiation injury in the intestine, was the highest in NT. Finally, SLI mice that had received NLC plus IL-7(-/-) NT transplantation plus IL-7 injection showed improved survival, weight recovery and an elevated number of CD4(+) T cells compared with the mice that had received NLC plus IL-7(-/-) NT or plus IL-7 injection alone. These findings suggest that NLCs plus NT transplantation can rescue SLI mice most effectively, and that high production of IL-7 in NT plays a crucial role with induction of CD4(+) T cells.
Asunto(s)
Síndrome de Radiación Aguda/terapia , Trasplante de Células Madre Hematopoyéticas/métodos , Hepatocitos/trasplante , Timo/trasplante , Animales , Animales Recién Nacidos , Linfocitos T CD4-Positivos , Modelos Animales de Enfermedad , Femenino , Supervivencia de Injerto , Interleucina-7/administración & dosificación , Interleucinas/administración & dosificación , Ratones , Análisis de Supervivencia , Timo/citología , Quimera por Trasplante , Irradiación Corporal TotalRESUMEN
It has recently been reported that antigen presentation from dendritic cells (DCs) to T cells occurs in the bone marrow, and that not only tumor antigen-pulsed DCs but also unpulsed DCs have some anti-tumor effects, resulting from the induction of anti-tumor immunity. In this paper, we examined whether dendritic cells induced from bone marrow cells (BMCs) have the capacity to suppress tumor growth and, if so, which route (intravenous, subcutaneous, or intra-bone marrow injection) is best. BALB/c mice that had been subcutaneously inoculated with Meth A (a murine fibrosarcoma cell line) were injected with BMC-derived DCs via the above three routes. We also examined the tumor suppressive effects of DCs from tumor-bearing mice. Although IBM injection showed similar effects to subcutaneous injection on the suppression of tumor growth, intravenous injection was less effective. It seems likely that the IBM injection of DCs activates tumor-specific T cells, resulting in the suppression of the tumor growth. DCs derived from tumor-bearing mice had some effects on the suppression of tumor growth but they were less effective than DCs from untreated mice.
Asunto(s)
Células Dendríticas/trasplante , Neoplasias Experimentales/terapia , Animales , Médula Ósea , Citocinas/genética , Citocinas/metabolismo , Inyecciones , Ratones , Ratones Endogámicos BALB C , Factores de TiempoRESUMEN
Granulocytes from human peripheral blood were co-cultured with conventional dendritic cells (cDC) or plasmacytoid DCs (pDC) to examine the effects of DCs on the activation or function of granulocytes. After co-culture of granulocytes with DCs, expression of the activation markers of granulocytes (CD63 and CD64) was up-regulated, and increased expression of CD50, the activation marker and ligand for CD209 (DC-SIGN) was also observed. The interaction of granulocytes with DCs was visualized as the cluster where DCs, especially cDCs, were surrounded by granulocytes to form a 'rosette'. After co-culture of granulocytes with cDCs, the secretion of elastase from granulocytes was enhanced significantly when examined cytohistochemically and by enzyme-linked immunosorbent assay. An increase in myeloperoxidase (another activation index of granulocytes) was also observed after co-culture with DCs. These findings suggest the functional and phenotypical activation of granulocytes by interaction with DCs. Furthermore, we examined the involvement of adhesion molecules in the granulocyte-DC interaction, and found that CD209 participates to some extent in this interaction.
Asunto(s)
Células Dendríticas/inmunología , Granulocitos/inmunología , Antígenos CD/metabolismo , Comunicación Celular , Técnicas de Cocultivo , Granulocitos/enzimología , Humanos , Inmunofenotipificación , Elastasa Pancreática/metabolismo , Glicoproteínas de Membrana Plaquetaria/metabolismo , Receptores de IgG/metabolismo , Formación de Roseta , Tetraspanina 30 , Regulación hacia ArribaRESUMEN
Current models of adult haematopoiesis propose that haematopoietic stem cells (HSCs) differentiate into common lymphoid (CLP) and common myeloid (CMP) progenitors and establish an early separation between myeloid and lymphoid lineages. Nevertheless, the developmental potential of CMP-associated B cells suggests the existence of alternate pathways for B lymphopoesis. The aim of this study was to compare the developmental and functional properties of CMP- and CLP-derived B cells. While both populations matured through pro-B cell and transitional B cell intermediates in the bone marrow and spleen, respectively, following transfer into irradiated mice, mature CMP- and CLP-derived B cells exhibit distinct functional responses. Specifically, CMP-derived B cells did not respond to mitogenic stimulation to the same degree as their CLP-derived counterparts and secrete lower levels of IgM and the inflammatory cytokines such as interleukin (IL)-6 and IL-10. Together, these data suggest the existence of multiple pathways for generating functionally distinct B cells from bone marrow precursors.
Asunto(s)
Subgrupos de Linfocitos B/inmunología , Linfopoyesis/inmunología , Células Progenitoras Mieloides/citología , Células Precursoras de Linfocitos B/citología , Traslado Adoptivo , Animales , Antígenos CD19/análisis , Células de la Médula Ósea/inmunología , Diferenciación Celular/inmunología , Células Cultivadas , Citocinas/biosíntesis , Inmunoglobulina M/biosíntesis , Ganglios Linfáticos/inmunología , Ratones , Ratones Endogámicos C57BL , Cavidad Peritoneal/citologíaRESUMEN
MRL/lpr mice (H-2(k)) with Fas gene mutation develop severe autoimmune diseases, and their haematolymphoid cells such as bone marrow and spleen cells showed a low apoptotic activity by irradiation. Therefore, conventional bone marrow transplantation (BMT) cannot be used to treat autoimmune diseases in these mice (chimeric resistance). In the present study, we examine the effects of additional adult thymus transplantation (TT) from the same donor on successful BMT. When the MRL/lpr mice were lethally irradiated (9 x 5Gy) and reconstituted with 3 x 10(7) of C57BL/6 mouse (H-2b) bone marrow cells (BMCs) in conjunction with TT, the mice significantly survived long term and showed a high donor-derived chimerism in comparison with those treated with BMT alone. Interestingly, the numbers of not only donor-derived T cells but also B cells increased significantly in the mice treated with BMT plus TT, even at the early phase of BMT. The number of aberrant CD3+B220+ cells decreased significantly, and the numbers of lymphocyte subsets were also normalized 4 weeks after the treatment. Finally, the autoimmune diseases in MRL/lpr mice could be cured by BMT with TT. These results indicate that the combination of BMT plus TT can overcome the chimeric resistance and treat the autoimmune diseases in MRL/lpr mice.
Asunto(s)
Enfermedades Autoinmunes/terapia , Trasplante de Médula Ósea/métodos , Timo/trasplante , Animales , Apoptosis/efectos de la radiación , Autoanticuerpos/sangre , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/patología , Células de la Médula Ósea/patología , Células de la Médula Ósea/efectos de la radiación , Trasplante de Médula Ósea/inmunología , Trasplante de Médula Ósea/patología , Femenino , Subgrupos Linfocitarios/inmunología , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos MRL lpr , Bazo/patología , Bazo/efectos de la radiación , Tasa de Supervivencia , Quimera por Trasplante , Resultado del TratamientoRESUMEN
The contribution of heme oxygenase HO-2, the primary source of bilirubin and carbon monoxide (CO) under physiological conditions, to the regulation of vascular function has remained largely unexplored. Using siRNA HO-2, we examined the effect of suppressed levels of HO-2 on vascular antioxidant and survival proteins. In vivo HO-2 siRNA treatment decreased the basal levels of EC-SOD, pAKT proteins (serine-473 and threonine-308), without changing Akt protein expression. HO-2 siRNA treatment increased 3-nitrotyrosine (3-NT) and apoptotic signaling kinase-1 (ASK-1) (P < 0.01). HO activity was decreased by the use of siRNA HO-2. We extended these studies to the mitochondria, examining for the presence of HO-1 and its role in the regulation of pro- and anti-apoptotic proteins. HO activity was increased by the administration of CoPP resulting in the translocation of HO-1 into the mitochondria, mainly to the inner face of the mitochondrial inner membrane. These findings suggest that HO-2 is critical in the maintenance of heme homeostasis and also the regulation of apoptosis by controlling levels of EC-SOD, Akt, 3-NT, and ASK-1. In addition, localization of HO-1 in the mitochondrial compartment plays a critical role in mitochondria-mediated apoptosis.
Asunto(s)
Hemo Oxigenasa (Desciclizante)/genética , Mitocondrias/metabolismo , Interferencia de ARN , Superóxido Dismutasa/metabolismo , Animales , Apoptosis/fisiología , Western Blotting , Hemo Oxigenasa (Desciclizante)/metabolismo , Hemo Oxigenasa (Desciclizante)/fisiología , Proteínas Proto-Oncogénicas c-akt/metabolismo , ARN Interferente Pequeño/genética , Ratas , Ratas Sprague-Dawley , Transducción de Señal/genética , Transducción de Señal/fisiología , Tirosina/análogos & derivados , Tirosina/metabolismo , Canal Aniónico 1 Dependiente del Voltaje/metabolismoRESUMEN
New Zealand Black (NZB) mice have multiple defects in both innate and acquired immunity. A fundamental defect, described more than 25 years ago, is premature thymic involution. Subsequent studies have disclosed multiple defects in thymic epithelial cells, and it has been proposed that thymic dendritic cells (DCs) play an important role not only in thymic involution but also in the appearance of immunopathology. However, the number of available thymic DCs makes this population extremely difficult to study. We have taken advantage of our ability to isolate pure populations of thymic DCs and have examined several key mRNA levels of enzymes involved in signal transduction. Our data on NZB mice was compared to that of NZB x NZW F1 (B/WF1), BXSB-Yaa, MRL/lpr, NOD and control mice. Importantly, we demonstrate herein that a common feature in autoimmune-prone mice is an increase of thymic DC c-met mRNA. Indeed, the increase in c-met mRNA levels appeared specific to the thymus and was not noted in the spleen. Additionally, we demonstrate that E-cadherin, a downstream molecule of c-met, is also reduced. Finally, we note that the levels of HGF mRNA are normal in the autoimmune strains examined herein, confirming that the abnormality of c-met mRNA is not due to primary defects in thymic stromal cells. We submit that these results highlight the possibility of a selective defect in thymic DCs which will be a pivotal step in loss of tolerance, and suggest that future studies focus on adoptive cell transfer involving this population.
Asunto(s)
Células Dendríticas/inmunología , Proteínas Proto-Oncogénicas c-met/metabolismo , ARN Mensajero/inmunología , Timo/inmunología , Animales , Autoinmunidad/inmunología , Cadherinas/biosíntesis , Cadherinas/metabolismo , Femenino , Factor de Crecimiento de Hepatocito/biosíntesis , Factor de Crecimiento de Hepatocito/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Endogámicos MRL lpr , Ratones Endogámicos NOD , Ratones Endogámicos NZB , Proteínas Proto-Oncogénicas c-met/biosíntesis , ARN Mensajero/genética , Células del Estroma/citología , Células del Estroma/inmunología , Timo/citologíaRESUMEN
Curative therapy for diabetes mellitus mainly involves pancreas or islet transplantation to recruit insulin-producing cells. This approach is limited, however, because of both the shortage of donor organs and allograft rejection. Intra-bone marrow bone marrow transplantation (IBM-BMT) has recently been shown to be effective in inducing donor-specific tolerance in mice and rats without the use of immunosuppressants. After induction of diabetes in 15 C3H mice with streptozotocin, the mice received both allotransplants of bone marrow cells from C57BL/6 mice by IBM-BMT and injections via the portal vein of insulin-producing cells that were induced in vitro from stem cells derived from adult C57BL/6 bone marrow. We evaluated the expression of these cells by examining the expression of not only insulin but also the crucial transcription factors insulin I and insulin II. The diabetic mice were treated with IBM-BMT and precultured insulin-producing cells. Hyperglycemia was normalized by 5 days after the treatment and remained normal for more than 45 days. This strategy might be applicable to patients with type I diabetes mellitus.
Asunto(s)
Células de la Médula Ósea , Trasplante de Médula Ósea , Diabetes Mellitus Experimental/terapia , Supervivencia de Injerto , Células Secretoras de Insulina/trasplante , Animales , Células de la Médula Ósea/metabolismo , Diabetes Mellitus Experimental/metabolismo , Regulación de la Expresión Génica , Humanos , Insulina/metabolismo , Células Secretoras de Insulina/metabolismo , Ratones , Ratones Endogámicos C3H , Vena Porta , Trasplante HomólogoRESUMEN
Gastric cancer metastasised to the liver was found to overexpress HER2 at a significantly higher incidence than primary gastric cancers. The purpose of the present study was to investigate the possibility of molecular therapy targeting HER2 overexpression in gastric cancer liver metastasis. We developed three new HER2-overexpressing gastric cancer cell lines (GLM-1, GLM-2, GLM-4) without epidermal growth factor receptor (EGFR) mutations derived from such liver metastasis, two of which had HER2 gene amplifications. All these GLM series of cell lines were highly sensitive to gefitinib in vitro, a specific inhibitor of EGFR tyrosine kinase (Iressa) rather than anti-HER2 antibody trastuzumab (Herceptin), whereas most of the HER2 low-expressing counterparts were not. In these HER2-overexpressing GLM series, protein kinase B (Akt), but not extracellular signal-regulated kinase 1/2 (ERK1/2), was constitutively phosphorylated, and gefitinib efficiently inhibited this Akt phosphorylation, induced strong apoptosis in vitro and exhibited antitumour activity in tumour xenografts in nude mice. This gefitinib-mediated antitumour effect in xenograft was significantly potentiated by trastuzumab treatment. On the other hand, gefitinib-resistant cells (GLM-1R) exhibited increased EGFR expression, followed by constitutive activation of mitogen-activated protein kinase (MAPK) pathway. These results suggest that the antitumour effect of gefitinib is due to the effective inhibition of HER2-driven constitutive activation of phosphatidylinositol-3-kinase (PI3K)/Akt pathway, and that the acquired resistance to gefitinib is due to the constitutive activation of Ras/MAPK pathway in compensation for PI3K/Akt pathway. Gastric cancer liver metastasis with HER2 overexpression would be a potential molecular target for gefitinib and trastuzumab.
Asunto(s)
Antineoplásicos/farmacología , Resistencia a Antineoplásicos/fisiología , Neoplasias Hepáticas/metabolismo , Quinazolinas/farmacología , Receptor ErbB-2/metabolismo , Neoplasias Gástricas/metabolismo , Animales , Western Blotting , Línea Celular Tumoral , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Gefitinib , Humanos , Inmunohistoquímica , Neoplasias Hepáticas/patología , Masculino , Ratones , Ratones Desnudos , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias Experimentales/metabolismo , Neoplasias Gástricas/secundarioRESUMEN
We have established a new method for allogeneic pancreatic islet (PI) transplantation: relatively low doses of irradiation followed by simultaneous transplantation of PIs and bone marrow cells (BMCs) via the portal vein (PV). In the present study, we have compared this method with intra-bone marrow (IBM)-bone marrow transplantation (BMT), and with a combination of both methods. Streptozotocin (STZ)-induced diabetic-recipient rats, Fischer 344 (F344, RT1A(l), RT1B(l)), were irradiated 1 day before transplantation. PIs of Brown Norway rats (BN, RT1A(n), RT1B(n)) were transplanted into the liver of the diabetic F344 rats via the PV. BMCs from BN rats were injected into the recipients' bone marrow (IBM), PV or intravenously (IV) or by a simultaneous combination of PV plus IBM (PV+IBM). We compared graft survival among the groups of '9 Gy+IBM'(10/10 accepted), '9 Gy+PV'(7/10 accepted), '9 Gy+IV'(0/7 accepted), '9 Gy+PV+IBM'(8/8 accepted), '8.5 Gy+IBM'(4/9 accepted), '8.5 Gy+PV'(0/7 accepted), '8.5 Gy+IV'(0/7 accepted), '8.5 Gy+PV+IBM'(9/12 accepted), '8 Gy+IBM'(2/10 accepted) and '8 Gy+PV+IBM'(2/8 accepted). As we reported previously, PV-BMT is more effective in inducing the acceptance of allogeneic PIs than IV-BMT. However, IBM-BMT requires less pretreatment than PV-BMT. (PV+IBM)-BMT was found to be the most effective in inducing the acceptance of allogeneic PIs. These results suggest that allogeneic PI-transplantation in conjunction with (PV+IBM)-BMT could become a viable strategy.